Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey.
Avram E DenburgAdam M FundytusMuhammad Saghir KhanScott C HowardFederico Antillon-KlussmannManju SengarDorothy Chilambe LombeWilma M HopmanMatthew JalinkBishal GyawaliDario TrapaniFelipe Santa Rosa RoitbergElisabeth G E De VriesLorenzo MojaGerald W PragerRichard SullivanChristopher M BoothPublished in: JCO global oncology (2022)
Most medicines that oncologists deem essential for childhood cancer treatment are currently included on the EMLc. Barriers remain in access to these medicines, characterized by gaps in availability and risks of catastrophic expenditure for families that are most pronounced in low-income settings but evident across all income contexts.